Fuda Cancer Hospital
| Қытай | Түркия | Австрия | |
| Өкпені алып тастау | бастап $24,000 | бастап $10,872 | бастап $50,000 |
| Өкпе рагында химиялық терапия | бастап $5,500 | бастап $1,000 | бастап $19,200 |
| Өкпе рагында сәулелік терапия | бастап $13,500 | бастап $4,000 | бастап $6,914 |
| Өкпе рагында иммундық терапия | бастап $4,200 | бастап $18,000 | бастап $30,000 |
| Өкпе рагын емдеу үшін операция | бастап $24,500 | бастап $17,000 | бастап $42,000 |
Сіз Bookimed қызметтері үшін төлемейсіз. өкпе рагының емдеудің бағалары клиниканың баға тізіміне сәйкес келеді. Сіз жеткенде тікелей клиникада төлейсіз. Бөліктермен төлеу қолжетімді.
Bookimed Сіздің қауіпсіздігіңізді қамтамасыз етеді. Біз тек өкпе рагының жүргізу үшін жоғары халықаралық стандарттарға сәйкес келетін клиникалармен ғана жұмыс істейміз. Олардың бүкіл әлем бойынша халықаралық науқастарға қызмет көрсету үшін қажетті лицензиялары бар.
Bookimed тегін көмек және қолдау ұсынады. Жеке медициналық координатор сапарға дейін, кезінде және кейін Сізбен байланыста. өкпе рагының емдеу кезінде Сіз басқа елде жалғыз қалмайсыз.
10 000-ға жуық криохирургиялық ота жасалды – профессор Ню Личжи Фуда онкологиялық ауруханасының аз инвазивті онкология бағдарламасын басқарады.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Доктор Ло Чжунчэньнің Фуда онкологиялық ауруханасында респираторлық медицина және клиникалық гематология саласында 20 жылдан астам тәжірибесі бар.
China provides high-quality lung cancer care through specialized oncology centers in Guangzhou, Shanghai, and Beijing. These JCI-accredited facilities offer advanced technologies like CyberKnife M6 and NanoKnife. High patient volumes allow surgeons to achieve remarkable procedural mastery in minimally invasive thoracic surgeries.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital treat 30,000+ international patients yearly. This massive data pool helps specialists refine protocols for advanced stages. Dr. Liuying at Jinshazhou Hospital even contributed to national expert consensus on lung tumor ablation. This level of specialization ensures that doctors see more complex cases in one month than many Western surgeons see in a year.
Patient Consensus: Patients note that top-tier care often rivals Western standards, especially for targeted therapies. They recommend hiring a private Mandarin translator and utilizing VIP departments to navigate language barriers effectively.
Advanced lung cancer therapies in China center on next-generation immunotherapy and high-precision minimally invasive procedures. Facilities utilize domestic breakthroughs like Ivonescimab alongside international standards. Molecularly targeted drugs for EGFR and ALK mutations are widely available. Treatment often integrates CyberKnife M6 radiosurgery and specialized cryosurgical ablation.
Bookimed Expert Insight: A major advantage for lung cancer patients in China is the massive scale of specialized centers. Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This high volume often translates to expertise in treating late-stage cancers. Patients can access specific technologies like NanoKnife that are less common in standard European or North American protocols.
Patient Consensus: Patients value the speed of enrollment for clinical trials and the affordability of genomic testing. Many suggest using official hospital mobile apps for scheduling to streamline care during their stay.
Top-tier Chinese hospitals for lung cancer treatment include JCI-accredited centers like Fuda Cancer Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences. These institutions offer advanced therapies such as cryosurgery, NanoKnife, and CyberKnife M6. They follow international NCCN guidelines while processing high patient volumes.
Bookimed Expert Insight: While high-profile national centers in Beijing handle massive volumes, private JCI-accredited hospitals like Fuda Cancer Hospital offer a significant coordination advantage. Dr. Niu Lizhi at Fuda has performed nearly 10,000 cryosurgeries. This specific procedural experience often exceeds that of western specialists. Choosing a clinic with such high individual doctor case numbers can lead to better precision in complex, minimally invasive lung procedures.
Patient Consensus: Patients note that while medical technology is advanced, having a professional coordinator is vital for navigating language barriers. Many emphasize that the high surgical volume translates to very experienced thoracic teams and modern immunotherapy options.
International patients manage lung cancer treatment in China through dedicated international departments providing on-site interpreters and logistical support. Facilities like Fuda Cancer Hospital serve over 30,000 global patients. Specialized coordinators handle medical visa invitations, airport transfers, and local housing to ensure seamless clinical transitions.
Bookimed Expert Insight: While many think Tier-1 cities are the only option, Guangzhou has emerged as a specialized hub for lung cancer. Fuda Cancer Hospital and Jinshazhou Hospital offer advanced technologies like Cryosurgery and CyberKnife M6. These centers prioritize international patients, with surgeons like Dr. Niu Lizhi having performed nearly 10,000 cryosurgeries.
Patient Consensus: Patients emphasize that hiring a private medical interpreter is essential for accurate dosing. They also suggest joining digital expat networks to navigate mobile payments and high-speed rail travel successfully.
International patients can secure remote second opinions for lung cancer treatment in China through virtual consultations or written reports. Leading facilities in Guangzhou and Shanghai use telemedicine to review pathology slides and CT scans. This process establishes treatment protocols and provides cost clarity before patients commit to international travel.
Bookimed Expert Insight: Bookimed data shows that packages for advanced therapies, such as the CyberKnife M6 at Jinshazhou Hospital, often include the initial video or text consultation as a standard service. This allows patients to confirm the technical feasibility of stereotactic radiosurgery before arrival. Dr. Zhang Yanjun and other specialists at this facility integrate these remote screenings to ensure the 56,000 CNY treatment cost is medically justified for the specific tumor stage.
Patient Consensus: Patients emphasize that sharing digital pathology slides is essential for accurate remote reviews. Many note that high-volume centers like Fuda Cancer Hospital provide preliminary assessments via digital channels to help clarify complex cases early.